Seres Therapeutics, Inc.MCRBNASDAQ
Loading
Year-over-year SG&A expense growth
Percentile
P5
Near historical low
vs 5Y Ago
-0.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -20.44% |
| Q3 2025 | -7.58% |
| Q2 2025 | -13.75% |
| Q1 2025 | -4.61% |
| Q4 2024 | -1.95% |
| Q3 2024 | -2.72% |
| Q2 2024 | -12.57% |
| Q1 2024 | -13.29% |
| Q4 2023 | -11.31% |
| Q3 2023 | -30.73% |
| Q2 2023 | 24.84% |
| Q1 2023 | 0.29% |
| Q4 2022 | 21.87% |
| Q3 2022 | -9.59% |
| Q2 2022 | 9.50% |
| Q1 2022 | -9.44% |
| Q4 2021 | 4.82% |
| Q3 2021 | 12.10% |
| Q2 2021 | 48.63% |
| Q1 2021 | 10.82% |
| Q4 2020 | 40.31% |
| Q3 2020 | 16.33% |
| Q2 2020 | 5.75% |
| Q1 2020 | 6.16% |
| Q4 2019 | -1.95% |
| Q3 2019 | 5.79% |
| Q2 2019 | -25.63% |
| Q1 2019 | -0.50% |
| Q4 2018 | -0.76% |
| Q3 2018 | -12.70% |
| Q2 2018 | -0.93% |
| Q1 2018 | -0.14% |
| Q4 2017 | 8.25% |
| Q3 2017 | -3.00% |
| Q2 2017 | -4.47% |
| Q1 2017 | 3.66% |
| Q4 2016 | 6.10% |
| Q3 2016 | -11.18% |
| Q2 2016 | 24.41% |
| Q1 2016 | 22.45% |